Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook, as they have multiple catalysts ahead including clinical trials and an Investor and Analyst Day scheduled in May 2026. Despite potential dilution from a recent offering, the company's strong balance sheet and differentiated late-stage cough asset, Haduvio, position them for success. However, there are risks to consider, such as clinical and regulatory risk, financing risk, and third-party risk.

Bears say

Trevi Therapeutics is strategically raising capital from a position of clinical momentum with the positive chronic cough data, allowing for improved financial flexibility in funding future development. Additionally, TRVI has plans for a larger Ph 3 study for key secondary endpoints to support an enhanced label and is planning a Ph 2b/3 non-IPF ILD trial in the second half of 2026, with potential launch in 2028. However, there is regulatory risk involved in gaining approval for IPF cough, RCC, and PN.

TRVI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 11 analysts, TRVI has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.